Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Penetra-EGF
- Development stage
- Preclinical
- Lead developer
- TIMEBIO
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Administration
- Topical
01
Overview
Penetra-EGF (also known as NCPP-EGF) is a preclinical-stage cell-penetrating peptide (CPP)-fused epidermal growth factor (EGF) developed by TIMEBIO. By fusing a cell-penetrating peptide to EGF, the platform enhances transdermal and intracellular delivery, allowing the growth factor to bypass the skin barrier and reach the deeper dermal layer. Penetra-EGF stimulates keratinocytes and fibroblasts, promoting cell proliferation, collagen synthesis, and tissue regeneration. It is being developed for cosmetic and therapeutic applications, including wrinkle reduction, skin elasticity improvement, wound healing, and hair loss/scalp care.
- Brand names
- Penetra-EGF
- Other names
- CPP-EGFCPP-fused epidermal growth factorNCPP-EGFPenetra-EGF™
02
Targets
Beyond the preview
Go deeper on Penetra-EGF.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Penetra-EGF.